Wockhardt is currently trading at Rs. 581.85, up by 3.20 points or 0.55% from its previous closing of Rs. 578.65 on the BSE.
The scrip opened at Rs. 580.00 and has touched a high and low of Rs. 583.25 and Rs. 579.85 respectively. So far 1018 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1012.00 on 08-Jan-2018 and a 52 week low of Rs. 531.50 on 22-Aug-2017.
Last one week high and low of the scrip stood at Rs. 586.85 and Rs. 549.20 respectively. The current market cap of the company is Rs. 6402.85 crore.
The promoters holding in the company stood at 74.10%, while Institutions and Non-Institutions held 9.90% and 16.00% respectively.
Wockhardt Group, a research based Global Pharmaceutical and Biotech major has set up its first facility in Middle East for manufacturing of New Chemical Entities (NCEs) catering to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG.
With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt inaugurated a 'state-of-the-art' manufacturing facility for the production and packaging of sterile dry powder injection in Dubai. On approval of the new drug by US Food and Drug Administration (USFDA), this manufacturing facility will be commissioned for commercial production.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.10 |
Dr. Reddys Lab | 1352.75 |
Cipla | 1510.25 |
Lupin | 2367.85 |
Zydus Lifesciences | 975.55 |
View more.. |